Andrew Lynch
@andrewlynch.io
Tumor evolution, genetic instability, and phenotype plasticity for precision medicine. TRIUMPH Postdoc @ MD Anderson Cancer Genomics and Evolution Lab
Reposted by Andrew Lynch
MD Anderson’s sarcoma team has received a $1.8M SPORE grant from the NCI to advance new immunologic and targeted sarcoma treatments.
The work includes a trial of adoptive cellular therapy for chordoma and a trial of antibody-drug conjugates for osteosarcoma.
#OncSky #EndCancer
The work includes a trial of adoptive cellular therapy for chordoma and a trial of antibody-drug conjugates for osteosarcoma.
#OncSky #EndCancer
August 25, 2025 at 5:28 PM
MD Anderson’s sarcoma team has received a $1.8M SPORE grant from the NCI to advance new immunologic and targeted sarcoma treatments.
The work includes a trial of adoptive cellular therapy for chordoma and a trial of antibody-drug conjugates for osteosarcoma.
#OncSky #EndCancer
The work includes a trial of adoptive cellular therapy for chordoma and a trial of antibody-drug conjugates for osteosarcoma.
#OncSky #EndCancer
Reposted by Andrew Lynch
Breaking news: The White House budget office on Wednesday rescinded an order freezing federal grants, according to a copy of a new memo obtained by The Post, after the administration’s move to halt spending earlier this week provoked a backlash.
White House rescinds freeze on federal grants, in reversal
The reversal followed criticism of the sudden freeze by the White House budget office.
wapo.st
January 29, 2025 at 6:00 PM
Breaking news: The White House budget office on Wednesday rescinded an order freezing federal grants, according to a copy of a new memo obtained by The Post, after the administration’s move to halt spending earlier this week provoked a backlash.
Relevant to many here — As of Dec 10, NCI is discontinuing the F32 and encouraging postdocs to apply for a K32 ACE award instead.
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
NOT-CA-25-013: Notice of the Discontinuation of NCI's Participation in PA-23-262 "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Notice of the Discontinuation of NCI's Participation in PA-23-262
grants.nih.gov
December 11, 2024 at 2:22 PM
Relevant to many here — As of Dec 10, NCI is discontinuing the F32 and encouraging postdocs to apply for a K32 ACE award instead.
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
grants.nih.gov/grants/guide...
Happy Evolution Day to those who celebrate.
November 24, 2024 at 2:39 PM
Happy Evolution Day to those who celebrate.
Great to connect with so many in my fields! The grass is greener (and sky bluer) on the other side.
I’m a postdoc at MD Anderson Cancer Center in Houston, TX. I study tumor evolution, genetic instability, phenotype plasticity, and their translational applications.
Great to see you all!
I’m a postdoc at MD Anderson Cancer Center in Houston, TX. I study tumor evolution, genetic instability, phenotype plasticity, and their translational applications.
Great to see you all!
November 21, 2024 at 11:44 PM
Great to connect with so many in my fields! The grass is greener (and sky bluer) on the other side.
I’m a postdoc at MD Anderson Cancer Center in Houston, TX. I study tumor evolution, genetic instability, phenotype plasticity, and their translational applications.
Great to see you all!
I’m a postdoc at MD Anderson Cancer Center in Houston, TX. I study tumor evolution, genetic instability, phenotype plasticity, and their translational applications.
Great to see you all!